198 related articles for article (PubMed ID: 24570327)
21. Analysis of the risk factors for contrast-induced nephropathy in over-aged patients receiving coronary intervention.
Pan HC; Wu XH; Wan QL; Liu And BH; Wu XS
Exp Biol Med (Maywood); 2018 Aug; 243(12):970-975. PubMed ID: 30299175
[TBL] [Abstract][Full Text] [Related]
22. Preventive effects of anisodamine against contrast-induced nephropathy in type 2 diabetics with renal insufficiency undergoing coronary angiography or angioplasty.
Geng W; Fu XH; Gu XS; Wang YB; Wang XC; Li W; Jiang YF; Hao GZ; Fan WZ; Xue L
Chin Med J (Engl); 2012 Oct; 125(19):3368-72. PubMed ID: 23044290
[TBL] [Abstract][Full Text] [Related]
23. Clinical outcomes of contrast-induced nephropathy in patients undergoing percutaneous coronary intervention: a prospective, multicenter, randomized study to analyze the effect of hydration and acetylcysteine.
Chen SL; Zhang J; Yei F; Zhu Z; Liu Z; Lin S; Chu J; Yan J; Zhang R; Kwan TW
Int J Cardiol; 2008 Jun; 126(3):407-13. PubMed ID: 17651830
[TBL] [Abstract][Full Text] [Related]
24. Brain natriuretic peptide for prevention of contrast-induced nephropathy after percutaneous coronary intervention or coronary angiography.
Liu JM; Xie YN; Gao ZH; Zu XG; Li YJ; Hao YM; Chang L
Can J Cardiol; 2014 Dec; 30(12):1607-12. PubMed ID: 25418218
[TBL] [Abstract][Full Text] [Related]
25. Trimetazidine can prevent the occurrence of contrast-induced nephropathy after percutaneous coronary intervention in elderly patients with renal insufficiency.
Fu H; Zhang J; Zhang H; Zhang P; Fu X; Zeng Z; Zhang X; Li W; Yang S; Liu X; Fu N
Perfusion; 2021 Sep; 36(6):603-609. PubMed ID: 32909511
[TBL] [Abstract][Full Text] [Related]
26. Continuous intravenous infusion of nicorandil for 4 hours before and 24 hours after percutaneous coronary intervention protects against contrast-induced nephropathy in patients with poor renal function.
Nawa T; Nishigaki K; Kinomura Y; Tanaka T; Yamada Y; Kawasaki M; Minatoguchi S
Int J Cardiol; 2015 Sep; 195():228-34. PubMed ID: 26048382
[TBL] [Abstract][Full Text] [Related]
27. The efficacy of probucol combined with hydration in preventing contrast-induced nephropathy in patients with coronary heart disease undergoing percutaneous coronary intervention: a multicenter, prospective, randomized controlled study.
Fu N; Yang S; Zhang J; Zhang P; Liang M; Cong H; Lin W; Tian F; Lu C
Int Urol Nephrol; 2018 Jan; 50(1):105-112. PubMed ID: 29071556
[TBL] [Abstract][Full Text] [Related]
28. A prospective, double-blind, randomized, controlled trial on the efficacy and cardiorenal safety of iodixanol vs. iopromide in patients with chronic kidney disease undergoing coronary angiography with or without percutaneous coronary intervention.
Nie B; Cheng WJ; Li YF; Cao Z; Yang Q; Zhao YX; Guo YH; Zhou YJ
Catheter Cardiovasc Interv; 2008 Dec; 72(7):958-65. PubMed ID: 19021282
[TBL] [Abstract][Full Text] [Related]
29. Comparison of effects of isotonic sodium chloride with diltiazem in prevention of contrast-induced nephropathy.
Beyazal H; Caliskan Z; Utaç C
Ren Fail; 2014 Apr; 36(3):351-5. PubMed ID: 24341598
[TBL] [Abstract][Full Text] [Related]
30. Prevention of contrast-induced nephropathy with single bolus erythropoietin in patients with diabetic kidney disease: A randomized controlled trial.
Shema-Didi L; Kristal B; Eizenberg S; Marzuq N; Sussan M; Feldman-Idov Y; Ofir P; Atar S
Nephrology (Carlton); 2016 Apr; 21(4):295-300. PubMed ID: 26370061
[TBL] [Abstract][Full Text] [Related]
31. Impact of anemia on contrast-induced nephropathy (CIN) in patients undergoing percutaneous coronary interventions.
Li WH; Li DY; Han F; Xu TD; Zhang YB; Zhu H
Int Urol Nephrol; 2013 Aug; 45(4):1065-70. PubMed ID: 23225080
[TBL] [Abstract][Full Text] [Related]
32. Impact of iso-osmolar versus low-osmolar contrast agents on contrast-induced nephropathy and tissue reperfusion in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention (from the Contrast Media and Nephrotoxicity Following Primary Angioplasty for Acute Myocardial Infarction [CONTRAST-AMI] Trial).
Bolognese L; Falsini G; Schwenke C; Grotti S; Limbruno U; Liistro F; Carrera A; Angioli P; Picchi A; Ducci K; Pierli C
Am J Cardiol; 2012 Jan; 109(1):67-74. PubMed ID: 21943940
[TBL] [Abstract][Full Text] [Related]
33. Elevated homocysteine and the risk of contrast-induced nephropathy: a cohort study.
Barbieri L; Verdoia M; Schaffer A; Niccoli G; Perrone-Filardi P; Bellomo G; Marino P; Suryapranata H; Luca GD
Angiology; 2015 Apr; 66(4):333-8. PubMed ID: 24830422
[TBL] [Abstract][Full Text] [Related]
34. Drug Effects and Clinical Investigations for Contrast-Induced Nephropathy After Coronary Angiography or Percutaneous Coronary Intervention in Patients With Diabetes.
Zhang MM; Lv QZ; Li XY
Am J Ther; 2017; 24(4):e423-e430. PubMed ID: 26308327
[TBL] [Abstract][Full Text] [Related]
35. Effects of liposomal prostaglandin E1 on periprocedural myocardial injury in patients with unstable angina undergoing an elective percutaneous coronary intervention.
Fan Y; Jiang Y; Fu X; Cai J; Wang Y; Li W; Gu X; Xing K; Bai S; Bi X
Coron Artery Dis; 2015 Dec; 26(8):671-7. PubMed ID: 26267747
[TBL] [Abstract][Full Text] [Related]
36. The use of nitrates in the prevention of contrast-induced nephropathy in patients hospitalized after undergoing percutaneous coronary intervention.
Peguero JG; Cornielle V; Gomez SI; Issa OM; Heimowitz TB; Santana O; Goldszer RC; Lamas GA
J Cardiovasc Pharmacol Ther; 2014 May; 19(3):310-4. PubMed ID: 24367008
[TBL] [Abstract][Full Text] [Related]
37. Contrast-Induced Nephropathy After Percutaneous Coronary Intervention for Chronic Total Occlusion Versus Non-Occlusive Coronary Artery Disease.
Demir OM; Lombardo F; Poletti E; Laricchia A; Beneduce A; Maccagni D; Slavich M; Giannini F; Carlino M; Margonato A; Cappelletti A; Colombo A; Azzalini L
Am J Cardiol; 2018 Dec; 122(11):1837-1842. PubMed ID: 30292337
[TBL] [Abstract][Full Text] [Related]
38. The ratio of contrast volume to glomerular filtration rate predicts outcomes after percutaneous coronary intervention for ST-segment elevation acute myocardial infarction.
Mager A; Vaknin Assa H; Lev EI; Bental T; Assali A; Kornowski R
Catheter Cardiovasc Interv; 2011 Aug; 78(2):198-201. PubMed ID: 20949583
[TBL] [Abstract][Full Text] [Related]
39. High Loading Dose of Atorvastatin for the Prevention of Serum Creatinine and Cystatin C-Based Contrast-Induced Nephropathy Following Percutaneous Coronary Intervention.
Fu N; Liang M; Yang S
Angiology; 2018 Sep; 69(8):692-699. PubMed ID: 29343076
[TBL] [Abstract][Full Text] [Related]
40. Febuxostat combined with hydration for the prevention of contrast-induced nephropathy in hyperuricemia patients undergoing percutaneous coronary intervention: A CONSORT-compliant randomized controlled trial.
Ma G; Li M; Teng W; He Z; Zhai X; Xia Z
Medicine (Baltimore); 2022 Jan; 101(4):e28683. PubMed ID: 35089218
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
